---  
layout: startup_page  
title: "NeoPhore Limited"  
id: "neophore.com"  
permalink: "/neophorelimitedneophore.com02012024/"  
website: "https://www.neophore.com/"  
funding_round: "Series B"  
funding_amount: "$39.5M"  
investors: "CPF managed by Sixth Element Capital, Claris Ventures, Astellas Venture Management, 3B Future Health Fund, 2investAG, NEVA SGR, LIFTT, Simon Fiduciaria"  
about: "NeoPhore Limited is a small molecule neoantigen immuno-oncology company developing a pipeline of drugs targeting proteins in the DNA mismatch repair pathway. Its first-in-class MMR inhibitors aim to increase immunogenicity in solid tumors, making them more responsive to immunotherapy. This approach seeks to improve clinical outcomes for cancer patients."  
markets: "Biotechnology, Drug Discovery, Small Molecule Therapeutics, Oncology, Immuno-oncology, Cancer, Genetics, and Translational Medicine"  
hq: "Cambridge, Cambridgeshire, United Kingdom"  
founded_year: "2017"  
linkedin: "https://www.linkedin.com/company/neophore-ltd"  
twitter: "https://twitter.com/neophoreltd"  
instagram: ""  
facebook: ""  
crunchbase: "https://www.crunchbase.com/organization/neophore"  
pitchbook: "https://pitchbook.com/profiles/company/222255-64"  

date_display: "01-Feb-2024"  
date: "2024-02-01"

# SEO Optimization  
meta_title: "NeoPhore Limited - Series B Funding ($39.5M)"  
meta_description: "NeoPhore Limited, NeoPhore Limited is a small molecule neoantigen immuno-oncology company developing a pipeline of drugs targeting proteins in the DNA mismatch repair p..."  
meta_keywords: "NeoPhore Limited, Biotechnology, Drug Discovery, Small Molecule Therapeutics, Oncology, Immuno-oncology, Cancer, Genetics, and Translational Medicine, Series B funding"  
canonical_url: "https://startup.projectstartups.com/neophorelimitedneophore.com02012024/"  
---